ZeroHarm Sciences raises ₹65 crore to expand nutraceutical platform globally

Sachin Darbarwar, Co-Founder & CEO of ZeroHarm Sciences

ZeroHarm Sciences, a nano-formulated plant-based nutraceutical model, efficiently closed a ₹65 crore funding spherical. Kotak Alternate Asset Managers, by way of its Kotak Life Sciences Fund I, has invested ₹40 crore, whereas Alkemi Development Capital, a healthcare and client wellness-focused enterprise fund, has invested ₹25 crore.

The capital will primarily be deployed by the Hyderabad-based firm to construct India’s first “Belief over Promise” well being platform, a mannequin by which complement efficacy is demonstrated by way of measurable client well being outcomes. Alongside this, ZeroHarm will put money into nationwide brand-building, worldwide enlargement throughout the USA, UK, and the Center East, and in scaling its vertically built-in R&D and manufacturing ecosystem.

“India’s complement market has a belief deficit — shoppers are requested to imagine claims they will by no means confirm. This funding permits us to change that equation essentially,’’ Sachin Darbarwar, Co-Founder & CEO of ZeroHarm Sciences, stated in a launch.

Ashish Ranjan, Director at Kotak Alts, stated: “The Indian nutraceuticals market is supported by beneficial macroeconomic, demand, and supply-side drivers. It stays within the early phases of adoption and is poised for exponential development. ZeroHarm is redefining preventive care and wellness by seamlessly integrating the timeless knowledge of Ayurveda with superior expertise, delivering options which are protected, efficient, and scalable.’’

“Sachin and the crew have constructed a uncommon mixture of farm-to-tablet integration, nano-formulation IP, and a powerful D2C engine. We’re excited to associate with them as they scale this platform nationally and globally,’’ Alka Goel, Founder & Managing Companion, Alkemi Development Capital stated.

Revealed on March 4, 2026